'Jardiance tab (empagliflozin, Boehringer Ingelheim Korea),' SGLT-2 class of treatment, is considered for expanding reimbursement to kidney disease, in addition to its current reimbursement for diabetes and cardiac failure.

As Forxiga, a competing drug in the same class as Jardiance, is expected to withdraw from the Korean market in the second half of the year, Jardiance’s expanded areas may lead to an increase in market share.

According to industry experts on the 25th, Jardiance 10 mg is undergoing review by the Health Insurance Review and Assessment Service (HIRA).

HIRA has recently received academic opinions and supplementary documents from the pharmaceutical c